Unruptured Intracranial Aneurysms

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AM-Pharma
AM-PharmaNetherlands - Utrecht
1 program
Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial AneurysmsN/A1 trial
Active Trials
NCT01490463CompletedEst. Jan 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AM-PharmaBrain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms

Clinical Trials (1)

NCT01490463AM-PharmaBrain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms

Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms

Start: Aug 2011Est. completion: Jan 2013
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space